Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

About this update from Capricor Therapeutics, Inc.

[{"type":"image","alt":"Capricor Therapeutics","displaySize":"","headline":null,"caption":"Capricor Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YaI1GjtfVRH2kLVsjMQa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7","width":300,"height":107}},"lazy":false},{"type":"text","content":"SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink’s Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida.","length":424,"tagName":"p"},{"type":"text","content":"Leerink’s Global Healthcare Conference 2025","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Presentation Date: Wednesday, March 12, 2025","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"Time: 1:00-1:40 p.m. ET","length":28,"tagName":"p"}]},{"val":[{"type":"text","content":"Webcast: Click here","length":19,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":96,"olType":false},{"type":"text","content":"Capricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates. For further information on this presentation, please visit Capricor's website at http://capricor.com/news/events/.","length":320,"tagName":"p"},{"type":"text","content":"About Capricor Therapeutics","length":27,"tagName":"p"},{"type":"text","content":"Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel, an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, an...

More updates from Capricor Therapeutics, Inc.